Roth Capital lowered the firm's price target on Niagen Bioscience to $12 from $13 and keeps a Buy rating on the shares. The company's Q1 results exceeded consensus estimates on all key metrics, with strong e-commerce sales offsetting lower sales to retail customers, the analyst tells investors in a research note.
